Confirm thalassemia diagnosis with region-tailored assays, and identify β-thalassemia modifiers.
Thalassemias are characterized by inherited defective hemoglobin synthesis leading to microcytic, hemolytic anemias. The clinical heterogeneity ranges from asymptomatic to very severe forms requiring regular blood transfusions. Globin StripAssays® detect common thalassemia-causing genetic variants worldwide, and the β-Thal Modifier StripAssay® identifies co-inherited variants known to ameliorate severity of beta-thalassemia.
Thalassemia
- Severe thalassemia is life-limiting and poses a major public health burden in Mediterranean countries, Africa, the Middle East, South-East Asia, and the Indian subcontinent.
- Mutations in the alpha- and beta-globin genes lead to reduced or abolished globin-chain synthesis or cause structurally abnormal hemoglobin.
- Genetic analysis is required to confirm the clinical diagnosis and is indispensable for genetic counseling.
- Apart from bone marrow transplantation, no ultimate cure is available up-to-date. However, identifying favorable genetic modifiers in patients help to predict the severity of beta-thalassemia phenotypes.
Products
|
Name
|
REF
|
Unit Size
|
IFU
|
Brochure
|
|---|---|---|---|---|
Name
α-Globin StripAssay®
|
REF
4-160
|
Unit Size
10 tests
|
IFU
|
Brochure
|
Name
β-Globin StripAssay® MED
|
REF
4-130
|
Unit Size
20 tests
|
IFU
|
Brochure
|
Name
β-Globin StripAssay® IME
|
REF
4-140
|
Unit Size
20 tests
|
IFU
|
Brochure
|
Name
β-Globin StripAssay® SEA
|
REF
4-150
|
Unit Size
20 tests
|
IFU
|
Brochure
|
Name
β-Thal Modifier StripAssay®
|
REF
4-170
|
Unit Size
20 tests
|
IFU
|
Brochure
|